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Summary Immunohistochemical expression of the tumour associated mucin-type glycoprotein A-80 was
investigated in a series of 173 breast cancer patients with a clinical follow-up between 13 and 19 years. A
routine immunoperoxidase technique was used in formalin-fixed, paraffin-embedded surgical tumour speci-
mens. One hundred and fifty of 173 tumours (87%) immunostained with MAb A-80. The degree of A-80
immunoreactivity was related to the tumour grade but not to lymph node status, tumour size, or nuclear DNA
distribution pattern. In univariate analysis the degree of A-80 expression was found to be of significant
prognostic value both in node negative and in node positive breast cancer patients (P = 0.03). Patients with
non-A-80 immunoreactive tumours had significant longer distant metastases-free survival times and fewer
relapses than women with carcinomas composed of A-80 immunoreactive tumour cells. This prognostic value
was reduced in a multivariate analysis, including lymph node status, tumour size, and nuclear DNA
distribution pattern, but retained borderline significance (P = 0.08). In conclusion, the findings of this study
indicate that expression of the mucin-type glycoprotein A-80 as determined by immunohistochemistry seems to
be related to clinical outcome in breast cancer patients.
Human breast cancer is a malignant disease with an often
unpredictable clinical course. Those clinico-pathological tum-
our characteristics in current use do not always give sufficient
information for the prediction of the individual tumour
behaviour. In the attempt to find additional 'markers' which
are associated with potential tumour aggression and in order
to get a better understanding of the tumour biology, num-
erous antibodies have been raised against various antigens of
human malignant tumours or their cell lines (Rittenhouse et
al., 1985). Though antibodies raised against glycoproteins
and proteins often are not organ specific and interestingly
also immunoreact with non-neoplastic and or foetal tissue,
close associations between the immunohistochemical expres-
sion of such glycoproteins and malignant tumours have been
reported (Rittenhouse et al., 1985).
In this context, the murine IgM monoclonal antibody A-80
has been raised against a purified high molecular weight
mucin-type glycoprotein derived from the human colon aden-
ocarcinoma cell line LS-147T (Gould et al., 1988; Jansson et
al., 1988). The A-80 antigen comprises heterogeneous glyco-
proteins with Mr ranging from 25 to greater than 200 kDa.
The antigenic epitope consists of both oligosaccharides and
polypeptides and N-acetylgalactosamine is an integral part
(Kim et al., 1991). The antibody has been shown to immuno-
stain neoplastic cells of carcinomas of the colon, pancreas,
prostate, lung, and breast (Jansson et al., 1988). In breast
disease, various degrees of immunohistochemical expression
of the A-80 antigen were not only found in the vast majority
of the malignant lesions, but also observed in benign pro-
liferative breast disease, especially in epithelial hyperplasias
with atypia (Jansson et al., 1988; Eriksson et al., 1992).
Against this background it was suggested that the antigen
recognised by monoclonal antibody A-80 might be a selec-
tive, epithelial, exocrine marker closely associated with malig-
nant transformation in breast disease. In order to investigate
the clinical importance of the presence and of the degree of
MAb A-80 immunostaining in mammary carcinomas, we
conducted an immunohistochemical study on surgical speci-
mens from breast cancer patients with a clinical follow up
between 13 and 19 years. The results were correlated with
other established prognostic factors, i.e. lymph node status,
tumour size, tumour grade, and nuclear DNA distribution
pattern.
Materials and methods
Patients
Tumour specimens from 173 patients with primary, operable
breast cancer were evaluated. All patients were treated at the
Radiumhemmet, Karolinska Hospital, from 1971 to 1976.
They were included in a randomised trial comparing pre-, or
postoperative radiation therapy to the chest wall and regional
lymph nodes (45 Gy within 5 weeks) with surgery alone. The
mean age was 56 (range 34-70 years). The surgical treatment
of all patients was a modified radical mastectomy with axil-
lary lymph node dissection. Only patients treated with
surgery alone or postoperative radiation were included in this
study because preoperative radiation might influence histo-
pathologic features as well as the lymph node status. No
patient received adjuvant systemic treatment. Details of the
trial design and results were reported previously (Rutqvist et
al., 1989). Patients were followed up for disease recurrence
and survival status as described elsewhere (Schimmelpenning
et al., 1990). For statistical analysis, follow-up information
available in December 1989 was used. This implied a mean
follow-up of 16 years (13-19 years). Histopathological
classification was based on the World Health Organisation
(WHO) histological typing of breast tumours (WHO 1981).
Immunohistochemistry
Immunohistochemical staining was performed with the avi-
din-biotin immunoperoxide complex (ABC) technique (Vec-
tastain ABC Kit, Mouse IgM, No. PK 4010. Tissue sections
of 4ytm thickness from routinely formalin-fixed and paraffin-
embedded specimens were dewaxed and dehydrated. The sec-
tions were then incubated with the monoclonal A-80 anti-
body, prepared from mouse ascites fluid (Kim et al., 1991), at
a dilution of 1:230 in TBS, containing 1% bovine serum
albumin and 0.015% sodium azide, at 8'C overnight.
Diaminobenzidine was used as chromogen. Finally, the speci-
mens were counterstained with Mayer's hematoxylin. Nega-
tive controls were sections of a known immunoreactive case
incubated with inactivated mouse serum instead of the pri-
mary antibody.
Tissue sections were classified as immunoreactive when a
distinct cytoplasmic staining pattern was observed. In con-
trast, a positive immunoreaction on intraluminal secretion
without co-existing cytoplasmic staining pattern was con-
sidered nonspecific. Immunohistochemical staining results
were evaluated as described previously (Eriksson et al., 1992).
The staining intensity was evaluated, and at the same time, a
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semi-quantitative assessment was carried out by estimating
the percentage of immunoreactive cells (Koukoulis et al.,
1990). Samples were graded from negative (-) to 3 +
positive: (- = less than 5%, 1 + = 5-20%, 2 + = 21-50%,
3 + = more than 50%).
Cytometrical DNA assessments and histogram evaluation
The nuclear DNA content was assessed by means of image
cytometry according the Feulgen technique as described
previously (Fallenius et al., 1986). The detailed DNA assess-
ment technique, including staining, internal standardisation,
and tumour cell selection was reported elsewhere (Fallenius
et al., 1988). The cytometrical DNA histograms were clas-
sified into four different types according to criteria described
by Auer et al. (1980). Type I histogram had a single distinct
peak in the diploid or near diploid region. Type II histo-
grams had a well circumscribed peak in the G2/M region of
the normal diploid population or two distinct peaks within
the GO/GI and the G2/M region, the latter containing at least
20% of all cell counts. Only a negligible number of cells
scattered between those two peaks or exceeded them. Histo-
grams of type III had a main peak in the GO/GI region of the
nomal cell population and a considerable number of scat-
tered cells in the S-phase region of that diploid peak, not
exceeding the G2/M region. Type IV histograms were charac-
terised by highly aneuploid DNA distribution patterns and
increased DNA values exceeding the normal G2/M region.
Statistical methods
Distant metastases-free survival was estimated and plotted by
use of actuarial methods and defined as the time from the
date of randomisation until the date of distant metastases, or
to the closing date at December 31, 1989 (Cutler & Ederer,
1958). Deaths that were not preceded by distant metastases
were censored at the time of death in the survival analysis.
Univariate and multivariate analyses were performed using
Cox's proportional hazards regression model (Cox, 1972).
The relationship between immunohistochemical A-80 expres-
sion and various histopathological features was analysed by
contingency tables (Armitage, 1971a,b).
Results
Immunohistochemical expression of the A-80 glycoprotein
was found in 150 (87%) of the 173 tumours. A detailed
analysis of the interrelationship between the degree of A-80
immunoreactivity and various histopathological tumour char-
acteristics is given in Table I. There was no statistically
significant interrelationship between the degree of A-80 ex-
pression, nodal status, tumour size, nor the cytometrical
DNA histogram type. Immunohistochemical A-80 expression
was observed in all the included histopathological subtypes
of mammary carcinomas and there was a direct association
between the grade of tumour cell differentiation and MAb
A-80 immunostaining. Poorly differentiated tumours were
characterised by significantly more frequently occurring
strong MAb A-80 immunoreaction patterns than tumour
variants with highly differentiated neoplastic cells (Figures
la-c).
In univariate analysis, the associations of the above men-
tioned tumour characteristics to distant metastases-free sur-
vival were investigated. The degree of immunohistochemical
A-80 expression was found to be of significant prognostic
value (P = 0.03) (Figure 2). Table II summarises the median
overall survival time and clinical follow-up data in relation to
MAb A-80 immunoreactivity. Patients with A-80 non-
immunoreactive tumours had a longer median survival than
those with tumours that A-80 immunostained (Table II).
Among the 23 patients with A-80 negative tumours there
were only three that died within 5 years after primary diag-
nosis of their neoplastic disease. The other 20 patients
survived more than 16 years with a median distant meta-
stases-free survival of 18 years. In contrast, patients with
tumours characterised by a strong A-80 immunostaining pat-
tern had a significantly shorter median overall survival time,
involved regional lymph nodes at the time of initial surgery
more often, and developed significantly more frequently local
recurrences and distant metastases (Table II).
Of the other tumour characteristics included in the
univariate analysis, nodal status, tumour size, and nuclear
DNA histogram type were also of significant prognostic
value (Table III). The histopathological tumour grade, treat-
ment and menopausal status were not related to the distant
Table I Interrelationship between immunohistochemical MAb A-80 expression,
nuclear DNA distribution pattern, and histopathological features in 173 patients with
primary invasive mammary carcinoma
Immunohistochemical A-80 expression
Absent Present Total General test of
(n = 23) (n = 150) (n = 173) association
Nodal status
pNO 14 (16) 73 (84) 87 x2= 1.2; P=0.28; n.s.
pN+ 9 (10) 77 (90) 86
Tumour size
<2cm 15 (15) 84 (85) 99 x2=2.4; P=0.49; n.s.
2-5cm 5 (10) 45 (90) 50
>5cm 1 (6) 15 (94) 16
Multiple 2 (25) 6 (75) 8
DNA histogram type
I 8 (17) 40 (83) 48 x2= 5.1; P=0.17; n.s.
II 7 (23) 23 (77) 30
III 1 (7) 14 (93) 15
IV 7 (9) 73 (91) 80
Histopathological
tumour type and grade
Ductal grade I 4 (33) 8 (67) 12 x2 = 6.3; P= 0.04
Ductal grade II 6 (9) 59 (61) 65
Ductal grade III 7 (10) 66 (90) 73
Lobular carcinomasa 4 (67) 2 (33) 6
Other carcinomasa 2 (12) 15 (88) 17
Percentages in brackets. aNot included in the test of general association. n.s. = not
significant.1420 E.T. ERIKSSON et al.
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Figure 1 a, Poorly differentiated infiltrating mammary carcinoma of ductal type with strong MAb A-80 immunostaining pattern
(ABC immunoperoxidase stain; magnification x 125). This tumour had an aneuploid DNA distribution pattern as measured in a
consecutive section of the same lesion. b, Same case as shown in a, at higher magnification. Note the strong staining pattern of
cytoplasmic granula in most of the neoplastic cells that is absent in the surrounding stroma cells. (ABC immunoperoxidase stain;
magnification x 400). c, Highly differentiated invasive mammary carcinoma of ductal type without MAb A-80 immunoreactive cells
(ABC immunoperoxidase stain; magnification x 125). This tumour had a diploid DNA distribution pattern as measured in a
consecutive section of the same lesion.
metastases-free survival (data not shown).
The results of a multivariate analysis, including nodal
status, tumour size, nuclear DNA histogram type, and MAb
A-80 expression are summarised in Table III. The prognostic
significance of MAb A-80 immunostaining was reduced but
retained borderline significance (P = 0.08). Nodal status,
tumour size, and nuclear DNA histogram type were found to
provide significant independent prognostic information.
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Figure 2 Immunohistochemical MAb A-80 expression and dis-
tant metastases-free survival in breast cancer patients (n = 173)
with a clinical follow-up between 13 and 19 years. The degree of
MAb A-80 expression was of significant prognostic information
for node negative and for node positive patients in univariate
analysis (P = 0.03). In multivariate analysis it retained borderline
significance (P = 0.08).
b
Discussion
Immunohistochemical expression of the A-80 antigen has
been observed in the vast majority of invasive mammary
carcinomas in an elaborate study by Koukoulis et al. (1990).
In the same study, most of the investigated benign mammary
lesions did not immunoreact with the MAb A-80. We con-
ducted a study comprising 204 invasive breast carcinomas
and found MAb A-80 immunostaining in 88% of the
tumours (Eriksson et al., 1992). However, the number of the
immunoreactive tumour cells and the intensity of immuno-
staining varied between tumour specimens. While in some
invasive tumours only about 5% of the neoplastic cells
immunostained, other malignant variants had more than 50%
immunoreactive cells. This observation was shared by others
(Koukoulis et al., 1990; Shin et al., 1989). Interestingly, in our
previous investigation we found A-80 non-immunoreactive
tumours to be often highly differentiated and of DNA
diploid type. In contrast, moderately and strongly A-80
immunostained carcinomas had often a lower grade of
differentiation and exhibited frequently aneuploid DNA dis-
tribution patterns (Eriksson et al., 1992). Against the back-
ground of these earlier findings, we conducted the present
study on the interrelationship between the immunohisto-
chemical A-80 expression, the nuclear DNA histogram type,
and the clinical course in breast cancer patients.
In univariate analysis, an interesting association between
the degree of immunohistochemical MAb A-80 expression
and the clinical course was found. The greatest difference in
distant metastases-free survival was observed between MAb
A-80 negative breast carcinomas and tumours with strong
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Table II Median overall survival time, clinical follow-up and nuclear DNA pattern
of 173 patients with mammary carcinoma in relation to MAb A-80 immunoreac-
tivity
Median Number of Number of Number of
Mab A-80 overall Number of patients with patients with DNA
immuno- survival time node positive local distant aneuploid
reactivity (years) tumours recurrence metastases tumours
Absent
(n = 23) 15 8 (35%) 3 (13%) 6 (26%) 8 (35%)
Present
1+(n=40) 12 18 (45%) 8 (20%) 21 (53%) 24 (60%)
2+(n=61) 12 34 (56%) 11 (18%) 27 (44%) 34 (56%)
3+(n=49) 10 25 (51%) 20 (41%) 29 (59%) 29 (59%)
Table III Univariate and multivariate analysis of the interrelationship between histo-
pathological and immunohistological tumour characteristics and distant-recurrence
free survival
No. of Adjusted rate
Parameter patients No. of events Crude rate ratio ratio'
Nodal status
pNO 87 31 1.0 X2=11.1 1.0 X2=6.1
pN + 86 82 2.1 P<0.001 1.8 P= 0.013
Tumour sizeb
<2 cm 99 41 1.0 X2 = 8.4 1.0 x2 = 6.5
2-5 cm 50 26 1.4 P = 0.038 1.2 P= 0.089
>5cm 16 11 2.5 2.4
Multiple 8 5 1.5 1.S
DNA histogram type
I 48 13 1.0 %2= 14.9 1.0 x2=9.9
II 30 14 2.2 P= 0.002 1.9 P= 0.019
III 15 10 3.8 3.6
IV 80 46 2.9 2.1
MAb-A-80
immunoreactivity
absent (-) 23 6 1.0 X2 = 9.2 1.0 X2= 6.7
present (1+) 40 21 2.6 P=0.027 2.4 P=0.081
(2+) 61 27 2.2 2.0
(3+) 49 29 3.5 3.0
bAdjusted for all factors listed as well as treatment and menopausal status. bMeasured on the surgical specimen.
immunostaining patterns of more than 50% of their neoplas-
tic cells (3 +). Invasive carcinomas with less intense MAb
A-80 expression (1 +, 2 +) represented an intermediate
group. Most of the distant metastases and relapses occurred
in the group of patients with MAb A-80 immunoreactive
tumours within the first 5 years after initial surgery. In
contrast, in the group of patients that had MAb A-80
negative tumours distant metastases occurred significantly
later. The frequency of events decreased after 5 years of
survival in both the A-80 immunoreactive and in the non-
immunoreactive group. It should be stressed that the degree
of the A-80 expression yielded significant prognostic informa-
tion not only in node positive, but also in node negative
breast cancer disease. In this context, it is noteworthy that
the intensively discussed prognostic value of some oncogene
products and other tumour associated proteins has mostly
been found in node positive breast cancer patients (Hayes et
al., 1991; Henry et al., 1990; Slamon et al., 1987).
In multivariate analysis, after adjustment for nodal status,
tumour size, and DNA histogram type, the prognostic effect
of A-80 expression was reduced to borderline significance.
One has to keep in mind, however, that the prognostic
significance of any new tumour parameter has to be con-
sidered against the strong statistical effects of the established
tumour characteristics with prognostic impact. Through
mammographic screening programs an increasing number of
breast cancers might be diagnosed in future. This might not
only include an increasing number of in situ carcinomas, but
also invasive carcinomas of small size without lymph node
involvement. Though patients with breast carcinomas of
small size generally tend to have a favourable clinical out-
come, some of these tumours have a more aggressive clinical
behaviour. It might thus become important to have addi-
tional 'markers' with prognostic impact at one's disposal also
in this group of patients. Here, it should be investigated
whether immunostaining with MAb A-80 might provide
additional prognostic information.
Several further results of this investigation merit discus-
sion. There was a significant association between MAb A-80
immunoreactivity and the histopathological tumour grade.
Tumour variants with a low grade of differentiation of their
neoplastic cells frequently expressed the A-80 glycoprotein
and seem thus to have an enhanced exocrine activity. As
mentioned above, we also found that breast carcinomas with
highly elevated levels of A-80 expression had a considerably
shorter distant metastases-free survival. In conclusion, these
observations might indicate that exocrine activity in breast
carcinomas could be associated with a more aggressive
clinical course. Interestingly, this is in contrast to previous
reports on A-80 expression in carcinomas of the colon and
stomach (Gould et al., 1988; Jansson et al., 1988). It was
found that A-80 negative tumours can have areas of neuroen-
docrine differentiation and were suggested to have a clinically
more aggressive behaviour. Our results show that there
appears to be an interesting difference in the clinical
significance of immunohistochemical MAb A-80 expression
between mammary carcinomas and malignant tumours of the
stomach and colon. In this study, A-80 negative carcinomas
were often highly differentiated and showed a less aggressive
clinical tumour behaviour. Whether there is an association
between the absence of MAb A-80 immunoreactivity and
neuroendocrine differentiation in breast carcinomas will be
the subject of a subsequent report.
The exact function of the mucin-type A-80 glycoprotein is
still unknown. However, some recent reports added further
information. Evidence has been obtained that the A-80 glyco-1422 E.T. ERIKSSON et al.
protein is present in foetal colonic epithelium and in
reparative, hyperplastic and benign neoplastic colon epi-
thelium, though at lower levels than in invasive colon car-
cinomas. Similar observations were made in breast tissue. We
found strong A-80 immunoreactivity in normal apocrine
sweat glands from the axilla (Eriksson et al., 1992). Interest-
ingly, aprocrine metaplasias frequently were also A-80 im-
munoreactive, which might indicate the close histogenetic
relationship between these two types of glands (Eriksson et
al., 1992). Against this background, one might suggest that
strong A-80 immunoreactivity in invasive breast carcinomas
might indicate a relatively low grade of histogenetic
differentiation. It is interesting to note that MAb A-80 exp-
ression seems to be associated with the genetic instability of a
tumour. This is indicated by the observation that absence of
A-80 immunoreactivity was frequently connected with
tumours of DNA diploid type. In contrast, elevated levels of
A-80 immunostaining were mostly observed in tumours of
DNA aneuploid type.
In conclusion, the findings of the present study indicate
that the degree of immunohistochemial expression of MAb
A-80 is closely related to the distant metastases-free survival
in breast cancer patients. Our pilot studies have shown that
MAb A-80 immunostaining can be performed in cytospin
preparations offine-needle aspirates taken from breast cancer
patients (Eriksson et al., 1992). It might thus be suggested
that these preoperatively taken samples might at an early
stage be included in a multifactor risk assessment for the
individual treatment of certain breast cancer patients.
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